SAN DIEGO — Illumina, Inc. (Nasdaq: ILMN) released its financial results for the third quarter of fiscal year 2026 on October 29, 2026, showcasing stronger-than-expected performance driven by clinical demand and NovaSeq X placements.
Chief Executive Officer Jacob Thaysen attributed the outperformance to solid market uptake. "In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance," Thaysen said. "As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes."
Supported by positive business momentum during the quarter, Illumina announced it is raising its full-year 2026 revenue and earnings guidance. The company closed the third quarter with $1.34 billion in cash, cash equivalents, and short-term investments, alongside a strong free cash flow of $378 million.
Source: Illumina, Inc. press release issued from San Diego on October 29, 2026.
